Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ENROLLING BY INVITATION
NCT07345858
Salivary Oxytocin as a Biomarker of Psychedelic Treatment
Sponsor: University of Geneva, Switzerland
View on ClinicalTrials.gov
Summary
This study aims to investigate whether oxytocin reactivity during a psychedelic session for MDD treatment predicts treatment response, specifically by examining its relationship with changes in flexibility and depressive symptoms.
Official title: Salivary Oxytocin as a Biomarker of Psychedelic Assisted Psychotherapy in Patients With Major Depressive Disorder
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
80
Start Date
2026-01-05
Completion Date
2026-10-30
Last Updated
2026-01-16
Healthy Volunteers
No
Conditions
Locations (1)
Geneva University Hospitals
Geneva, Switzerland